中国P站

Biofilms; Chronic wounds; Antimicrobial resistance; Wound healing; Therapeutic strategies; Host-pathogen interactions; Novel treatments; Diagnostics; Biofilm disruption; Quorum sensing inhibitors

Introduction

Chronic wounds present a significant clinical challenge, often complicated by the presence of bacterial biofilms. These biofilms play a crucial role, impacting delayed healing and increasing antimicrobial resistance, necessitating novel approaches for therapeutic management [1].

They represent a persistent form of infection, difficult to diagnose, and require treatments that go beyond conventional antibiotic methods to effectively disrupt and eliminate them. The complex interplay between host defenses and invading pathogens during the formation of biofilms in chronic wounds is a critical area of study [2].

Understanding these interactions is vital to overcome current treatment hurdles and devise therapeutic strategies that can modulate the host response while directly targeting the biofilm matrix itself. The ultimate goal is to significantly improve wound healing outcomes. Significant progress has been made recently in strategies for combating these biofilm-associated chronic wound infections [3].

This includes moving beyond traditional antimicrobial agents to explore innovative therapeutic options. Emerging methods encompass the use of antimicrobial peptides, bacteriophages, and advanced nanotechnology-based approaches, all designed with the specific purpose of disrupting biofilms and accelerating wound recovery. Bacterial biofilms critically impact persistent wound infections, impeding the healing process and contributing directly to antibiotic resistance [4].

Reviewing current management strategies reveals that therapeutic interventions, such as debridement and targeted antimicrobial therapies, are constantly being refined to effectively address these complex challenges. However, complete eradication remains elusive. A broad overview of existing and emerging therapies for eradicating biofilms in chronic wound infections highlights diverse approaches [5].

Scoping reviews consider mechanical, chemical, and biological strategies, offering insights into their efficacy and the considerable challenges linked with achieving thorough biofilm removal to promote wound healing. The latest advancements in diagnosing and treating chronic wound infections underscore the pivotal role of biofilms [6].

There is a growing emphasis on improved diagnostic tools for detecting biofilms, coupled with the development of cutting-edge therapeutic modalities. These include specialized dressings and novel biofilm-disrupting agents, all aimed at enhancing clinical outcomes in these particularly challenging cases. An updated perspective on biofilms in chronic wounds reveals that conventional treatments often face significant resistance [7].

Exploring innovative interventions, such as specific anti-biofilm agents and combination therapies, is essential to overcome these hurdles. The objective is to improve wound healing by targeting the unique resistance mechanisms of biofilms. Investigating new strategies to disrupt bacterial biofilms in chronic wounds is yielding promising results [8].

This research focuses on innovative methods that specifically target the biofilm structure and metabolism. Examples include quorum sensing inhibitors, various enzymes, and bacteriophages, offering alternatives to traditional antibiotics for more effective biofilm eradication and enhanced wound care. Treating biofilm-associated chronic wounds presents significant challenges, primarily due to the biofilm's protective matrix and inherent resistance mechanisms [9].

A comprehensive review points to current limitations in therapy and advocates for multidisciplinary approaches to achieve more effective management and better patient outcomes. Ultimately, biofilms act as a significant barrier to effective wound healing [10].

Examining the underlying mechanisms and their implications for chronic wound management is crucial. Various therapeutic strategies, including biofilm dispersal techniques and novel antimicrobial agents, are being developed to overcome this barrier and accelerate the healing process.

Description

Chronic wounds are a major health concern, frequently complicated by the presence of bacterial biofilms, which are communities of microorganisms encased in an extracellular matrix. These biofilms are widely recognized for their significant role in delaying wound healing and contributing to the global challenge of antimicrobial resistance [1, 4]. The persistent nature of these infections presents considerable difficulties in accurate diagnosis, often requiring advanced methods beyond standard microbiological cultures. Moving past conventional antibiotic strategies is essential for effective intervention, as biofilms inherently resist many common treatments [1, 7].

The formation of biofilms involves complex interactions between the host's immune system and various pathogens, creating an environment where bacteria are protected from both host defenses and therapeutic agents [2, 9]. This protective matrix and the unique physiology of biofilm-dwelling bacteria contribute to their recalcitrance, complicating therapy significantly. Biofilms effectively act as a physical barrier, impeding the normal progression of wound healing and creating a chronic inflammatory state that further delays closure [10]. Current hurdles in treating these infections stem from this intricate interplay, necessitating strategies that can both modulate the host response and directly target the biofilm structure [2, 9].

Existing management strategies for chronic wound infections often include mechanical debridement, along with topical or systemic antimicrobial therapies [4, 5]. However, achieving complete eradication of biofilms through these conventional methods remains a substantial challenge, as evidenced by ongoing infection and recurrence [5, 7]. Many traditional antimicrobial agents struggle to penetrate the biofilm matrix or effectively kill quiescent bacteria residing within it. This underscores the need for innovative approaches that extend beyond the limitations of current practices and can truly disrupt the protective environment biofilms create [3, 7].

Recent years have seen a surge in innovative strategies aimed at combating biofilm-associated chronic wound infections. These emerging therapeutic options are designed to directly disrupt the biofilm's structure and metabolism, offering promising alternatives to traditional antibiotics [1, 3, 8]. For example, antimicrobial peptides and bacteriophages are being explored for their ability to specifically target bacterial cells within biofilms or dismantle the matrix itself [3, 8]. Nanotechnology-based approaches also hold significant promise for delivering agents precisely to the biofilm site, enhancing their efficacy and minimizing systemic side effects [3].

Furthermore, advancements extend to diagnostic tools, with a focus on improving the detection of biofilms in clinical settings, which is crucial for timely and appropriate intervention [6]. On the treatment front, specialized dressings infused with anti-biofilm agents and novel biofilm-disrupting compounds are being developed to enhance clinical outcomes [6, 10]. Other strategies include targeting quorum sensing inhibitors, which interfere with bacterial communication essential for biofilm formation, and utilizing enzymes that degrade the extracellular polymeric substance [8, 10]. These varied mechanical, chemical, and biological strategies collectively represent a multidisciplinary effort to overcome the persistent challenge of biofilms and improve the prognosis for patients with chronic wounds [5, 9]. The overarching goal is to effectively eradicate biofilms, accelerate healing, and mitigate the rising threat of antimicrobial resistance.

Conclusion

Chronic wounds often harbor biofilms, which are complex communities of bacteria that significantly impede healing and contribute to increased antimicrobial resistance. These persistent infections pose considerable diagnostic challenges and complicate conventional antibiotic treatments. Biofilms act as a physical barrier to effective wound healing, due to their protective matrix and inherent resistance mechanisms. Understanding the intricate interactions between host defenses and pathogens during biofilm formation is crucial for developing better interventions. Current research highlights the necessity of moving beyond traditional antimicrobial agents to address these issues. Existing management strategies, including debridement, often fall short in achieving complete biofilm eradication. Consequently, there's a strong focus on exploring innovative therapeutic methods. Recent advancements in combating biofilm-associated infections involve a range of novel approaches. These include strategies designed to disrupt the biofilm structure and metabolism, such as antimicrobial peptides, bacteriophages, and nanotechnology-based solutions. Some promising alternatives target quorum sensing inhibitors or employ enzymes to dismantle the biofilm matrix. Furthermore, improved diagnostic tools are emerging for better biofilm detection. Therapeutic modalities are evolving to include specialized dressings, biofilm-disrupting agents, and combination therapies. The aim is to modulate the host response and directly target the biofilm to enhance recovery, ultimately overcoming the limitations of conventional treatments and fostering more effective wound healing. Various mechanical, chemical, and biological strategies are under investigation to improve outcomes.

References

1. Kenneth PR, Hira H, David JN (2023) .J Wound Care 32:100-110.

   , ,

2. Faezeh G, Alireza R, Mostafa Z (2023) .Microorganisms 11:1966.

   , ,

3. Haodi M, Wenshi L, Xin L (2022) .Molecules 27:6324.

   , ,

4. S M, V M, N O (2022) .J Wound Care 31:S24-S32.

   , ,

5. P M, Z A, S DC (2021) .J Wound Care 30:S12-S19.

   , ,

6. Martin M, Darla MG, Gregory S (2020) .J Wound Care 29:S20-S26.

   , ,

7. Laura R, Emanuele M, Riccardo C (2021) .Exp Gerontol 156:111451.

   , ,

8. Sweta S, Anshika D, Gaurav R (2023) .J Appl Microbiol 135:lxad114.

   , ,

9. Meng S, Yujia L, Yuqi L (2022) .Antibiotics (Basel) 11:1216.

   , ,

10. Shujuan Y, Yong L, Jianan X (2023) .Front Cell Infect Microbiol 13:1118685.

    , ,